Search for Clinical Trial Results

Sponsored By

Lymphoma, Primary Effusion - 7 Studies Found

Status Study
Recruiting Study Name: Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma
Condition: AIDS-Related Primary Effusion Lymphoma
Date: 2016-07-01
Interventions:
  • Genetic: Laboratory Biomarker Analysis

Completed Study Name: Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
Condition: Lymphoma
Date: 2005-09-20
Interventions:
  • Biological: bevacizumab
  • Biological: filgra
Terminated Study Name: Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
Condition:
  • Non-Hodgkin's Lymphoma
  • Burkitt Lymphoma
  • AIDS-Related Diffuse Large Cell Lymphoma
  • AIDS-Related Plasmablastic Lymphoma
  • Date: 2010-09-01
    Interventions:
    • Drug: Cyclophosphamide Given I
Recruiting Study Name: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Condition:
  • AIDS-Related Burkitt Lymphoma
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • Drug: Prednisone Given PO
Not yet recruiting Study Name: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Condition:
  • Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
  • ALK-Positive Large B-Cell Lymphoma

    • Date: 2017-01-31
    Interventions:
    • Other: Laboratory Biomarker Analysis

NOT_YET_RECRUITING Study Name: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
Condition:
Date: 2025-02-09
Interventions: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses